vs
CECO ENVIRONMENTAL CORP（CECO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是CECO ENVIRONMENTAL CORP的1.1倍（$219.9M vs $205.9M），CECO ENVIRONMENTAL CORP同比增速更快（16.5% vs 2.0%），过去两年CECO ENVIRONMENTAL CORP的营收复合增速更高（22.4% vs 8.0%）
CECO环保是1966年成立的美国工业技术企业，总部位于得克萨斯州达拉斯，在纳斯达克上市，股票代码为CECO。公司面向制造、化工、能源、炼油等工业领域，提供空气污染治理相关的技术、产品及服务，助力工业客户满足环保排放要求。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CECO vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$205.9M
营收增速更快
CECO
高出14.6%
2.0%
两年增速更快
CECO
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.9M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 31.0% | 71.1% |
| 营业利润率 | 0.9% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 16.5% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.98 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CECOOFIX
| Q1 26 | $205.9M | — | ||
| Q4 25 | $214.7M | $219.9M | ||
| Q3 25 | $197.6M | $205.6M | ||
| Q2 25 | $185.4M | $203.1M | ||
| Q1 25 | $176.7M | $193.6M | ||
| Q4 24 | $158.6M | $215.7M | ||
| Q3 24 | $135.5M | $196.6M | ||
| Q2 24 | $137.5M | $198.6M |
净利润CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $3.1M | $-2.2M | ||
| Q3 25 | $1.5M | $-22.8M | ||
| Q2 25 | $9.5M | $-14.1M | ||
| Q1 25 | $36.0M | $-53.1M | ||
| Q4 24 | $4.9M | $-29.1M | ||
| Q3 24 | $2.1M | $-27.4M | ||
| Q2 24 | $4.5M | $-33.4M |
毛利率CECOOFIX
| Q1 26 | 31.0% | — | ||
| Q4 25 | 35.1% | 71.1% | ||
| Q3 25 | 32.7% | 72.2% | ||
| Q2 25 | 36.2% | 68.7% | ||
| Q1 25 | 35.2% | 62.8% | ||
| Q4 24 | 35.8% | 69.0% | ||
| Q3 24 | 33.4% | 68.7% | ||
| Q2 24 | 35.7% | 67.8% |
营业利润率CECOOFIX
| Q1 26 | 0.9% | — | ||
| Q4 25 | 7.7% | 0.2% | ||
| Q3 25 | 4.8% | -8.3% | ||
| Q2 25 | 9.7% | -7.9% | ||
| Q1 25 | 35.0% | -25.2% | ||
| Q4 24 | 7.1% | -5.3% | ||
| Q3 24 | 5.3% | -9.6% | ||
| Q2 24 | 6.7% | -12.5% |
净利率CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | -1.0% | ||
| Q3 25 | 0.8% | -11.1% | ||
| Q2 25 | 5.1% | -6.9% | ||
| Q1 25 | 20.4% | -27.4% | ||
| Q4 24 | 3.1% | -13.5% | ||
| Q3 24 | 1.5% | -13.9% | ||
| Q2 24 | 3.3% | -16.8% |
每股收益（稀释后）CECOOFIX
| Q1 26 | $0.98 | — | ||
| Q4 25 | $0.09 | $-0.05 | ||
| Q3 25 | $0.04 | $-0.57 | ||
| Q2 25 | $0.26 | $-0.36 | ||
| Q1 25 | $0.98 | $-1.35 | ||
| Q4 24 | $0.14 | $-0.76 | ||
| Q3 24 | $0.06 | $-0.71 | ||
| Q2 24 | $0.12 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.4M | $82.0M |
| 总债务越低越好 | $5.3M | — |
| 股东权益账面价值 | $317.2M | $450.0M |
| 总资产 | $1.0B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CECOOFIX
| Q1 26 | $45.4M | — | ||
| Q4 25 | $33.1M | $82.0M | ||
| Q3 25 | $32.8M | $62.9M | ||
| Q2 25 | $36.8M | $65.6M | ||
| Q1 25 | $146.5M | $58.0M | ||
| Q4 24 | $37.8M | $83.2M | ||
| Q3 24 | $38.7M | $30.1M | ||
| Q2 24 | $36.5M | $26.4M |
总债务CECOOFIX
| Q1 26 | $5.3M | — | ||
| Q4 25 | $212.4M | — | ||
| Q3 25 | $220.9M | $157.2M | ||
| Q2 25 | $238.7M | $157.0M | ||
| Q1 25 | $339.7M | $156.9M | ||
| Q4 24 | $218.9M | $157.0M | ||
| Q3 24 | $133.4M | $118.5M | ||
| Q2 24 | $130.8M | $118.0M |
股东权益CECOOFIX
| Q1 26 | $317.2M | — | ||
| Q4 25 | $317.5M | $450.0M | ||
| Q3 25 | $309.2M | $442.5M | ||
| Q2 25 | $298.4M | $458.3M | ||
| Q1 25 | $285.8M | $458.3M | ||
| Q4 24 | $247.7M | $503.1M | ||
| Q3 24 | $241.3M | $525.9M | ||
| Q2 24 | $235.0M | $546.0M |
总资产CECOOFIX
| Q1 26 | $1.0B | — | ||
| Q4 25 | $893.8M | $850.6M | ||
| Q3 25 | $891.9M | $832.6M | ||
| Q2 25 | $876.6M | $837.2M | ||
| Q1 25 | $957.1M | $823.1M | ||
| Q4 24 | $759.7M | $893.3M | ||
| Q3 24 | $621.5M | $867.9M | ||
| Q2 24 | $598.1M | $882.0M |
负债/权益比CECOOFIX
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.71× | 0.36× | ||
| Q2 25 | 0.80× | 0.34× | ||
| Q1 25 | 1.19× | 0.34× | ||
| Q4 24 | 0.88× | 0.31× | ||
| Q3 24 | 0.55× | 0.23× | ||
| Q2 24 | 0.56× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $10.0M | $27.7M | ||
| Q3 25 | $15.3M | $12.4M | ||
| Q2 25 | $-7.7M | $11.6M | ||
| Q1 25 | $-11.7M | $-18.4M | ||
| Q4 24 | $1.8M | $23.7M | ||
| Q3 24 | $15.1M | $11.7M | ||
| Q2 24 | $6.7M | $9.0M |
自由现金流CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $16.8M | ||
| Q3 25 | $11.0M | $2.5M | ||
| Q2 25 | $-8.7M | $4.5M | ||
| Q1 25 | $-15.1M | $-25.1M | ||
| Q4 24 | $-4.3M | $15.2M | ||
| Q3 24 | $11.1M | $6.3M | ||
| Q2 24 | $2.5M | $-360.0K |
自由现金流率CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 7.6% | ||
| Q3 25 | 5.6% | 1.2% | ||
| Q2 25 | -4.7% | 2.2% | ||
| Q1 25 | -8.5% | -13.0% | ||
| Q4 24 | -2.7% | 7.0% | ||
| Q3 24 | 8.2% | 3.2% | ||
| Q2 24 | 1.9% | -0.2% |
资本支出强度CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 4.9% | ||
| Q3 25 | 2.1% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 1.9% | 3.5% | ||
| Q4 24 | 3.9% | 4.0% | ||
| Q3 24 | 3.0% | 2.7% | ||
| Q2 24 | 3.0% | 4.7% |
现金转化率CECOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 3.26× | — | ||
| Q3 25 | 10.18× | — | ||
| Q2 25 | -0.81× | — | ||
| Q1 25 | -0.33× | — | ||
| Q4 24 | 0.37× | — | ||
| Q3 24 | 7.24× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CECO
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
